Citation only
via OpenAlex
Pharmacological Advances in the Treatment of Age-related Macular Degeneration
María Gil‐Martínez, Paz Santos-Ramos, Maribel Fernández-Rodríguez, Maximino José Abraldes, María José Rodríguez‐Cid, María Santiago-Varela, Anxo Fernández‐Ferreiro, Francisco Gómez‐Ulla
Current Medicinal Chemistry · 2019 · ▲ 57 citations
Abstract
Age-related macular degeneration is an acquired degenerative disease that is responsible for severe loss of vision in elderly people. There are two types: dry age-related macular degeneration and wet age-related macular degeneration. Its treatment has been improved and tries to be tailored in the future. The aim of this review is to summarize the pharmacological advances in the treatment of age-related macular degeneration. Regarding dry AMD, there is no effective treatment to reduce its progression. However, some molecules such as lampalizumab and eculizumab were under investigation, although they have shown low efficacy. Herein, in an attempt to prevent dry AMD progression, the most important studies suggested increasing the antioxidants intake and quitting the smoke habit. On the other hand, wet AMD has more developed treatment. Nowadays, the gold standard treatment is anti-VEGF injections. However, more effective molecules are currently under investigation. There are different molecules under research for dry AMD and wet AMD. This fact could help us treat our patients with more effective and lasting drugs but more clinical trials and safety studies are required in order to achieve an optimal treatment.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.2174/0929867326666190726121711
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Gil‐Martínez, M., Santos-Ramos, P., Fernández-Rodríguez, M., Abraldes, M.J., Rodríguez‐Cid, M.J., Santiago-Varela, M., Fernández‐Ferreiro, A., & Gómez‐Ulla, F. (2019). Pharmacological Advances in the Treatment of Age-related Macular Degeneration. <em>Current Medicinal Chemistry</em>. https://doi.org/10.2174/0929867326666190726121711
Vancouver
Gil‐Martínez M, Santos-Ramos P, Fernández-Rodríguez M, Abraldes MJ, Rodríguez‐Cid MJ, Santiago-Varela M, et al. Pharmacological Advances in the Treatment of Age-related Macular Degeneration. Current Medicinal Chemistry. 2019. doi:10.2174/0929867326666190726121711.
BibTeX
@article{mara2019Pharma,
title = {Pharmacological Advances in the Treatment of Age-related Macular Degeneration},
author = {María Gil‐Martínez and Paz Santos-Ramos and Maribel Fernández-Rodríguez and Maximino José Abraldes and María José Rodríguez‐Cid and María Santiago-Varela and Anxo Fernández‐Ferreiro and Francisco Gómez‐Ulla},
journal = {Current Medicinal Chemistry},
year = {2019},
doi = {10.2174/0929867326666190726121711},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nature reviews. Immunology 2013
Preprint · OA
Immunology of age-related macular degeneration
Genaera Corporation 2004
Open access · US-GOV
A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Advanced Drug Delivery Reviews 2005
Citation only
Wet age-related macular degeneration
Developments in ophthalmology 2015
Citation only
Neovascular Age-Related Macular Degeneration
Oxidative Medicine and Cellular Longevity 2018
Open access · CC-BY
Age‐Related Macular Degeneration: New Paradigms for Treatment and Management of AMD
Control Delivery Systems 2001
Open access · US-GOV